A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or stop disease progression. Research has identified a critical DNA repair ...
Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative ...
Hosted on MSN
What Happens in Huntington’s Disease?Huntington’s disease is a hereditary disorder that causes a progressive decline in thinking, memory, and the control of movements. On average, the symptoms begin when a person is in their early 40s, ...
October was an insight-rich month in Huntington’s disease research: additional clarity around uniQure’s AMT-130, mapping how and where HD changes the brain, early mechanistic studies targeting DNA ...
For decades, so many families have watched loved ones suffer from Huntington's disease, a neurodegenerative condition that progressively worsens over time. But now, there is finally a light at the end ...
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...
Doctors have announced the first successful treatment for Huntington’s disease, a devastating inherited condition that combines symptoms of dementia, Parkinson’s and motor neurone disease. The ...
UniQure, said on Monday the U.S. Food & Drug Administration has deemed clinical data for its gene therapy for Huntington's ...
Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and devastating neurodegenerative disorder, at his clinic at the University of Alabama at Birmingham. But last ...
The first signs of Huntington’s disease are often subtle changes in coordination, such as clumsiness or trouble with balance. You may also begin to notice changes in thinking, such as difficulty ...
AMT-130, aimed at treating Huntington’s disease (HD). This article will delve into the recent feedback from the U.S. Food and Drug Administration (FDA), the implications for the therapy's regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results